1 / 38

Antianemeic drugs

Antianemeic drugs. Agents to Tr anemia Dr Alia Alshanawani. Hematopoiesis : production of erythrocytes, platelets, & leukocytes from stem cells in ! Bone marrow. Require a constant supply of 3 essential nutrients: - Iron - Vitamin B 12 - Folic acid + hematopoietic growth factors.

Download Presentation

Antianemeic drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. Antianemeic drugs Agents to Tr anemia Dr Alia Alshanawani

  2. Hematopoiesis: production of erythrocytes, platelets, & leukocytes from stem cells in ! Bone marrow. • Require a constant supply of 3 essential nutrients: - Iron - Vitamin B12 - Folic acid + hematopoietic growth factors. Anemia: deficiency in O2-carrying erythrocytes.

  3. Anti-anemic drugs In iron deficiency & other hypochromic anemia: • Iron • Pyridoxine, Riboflavin, Copper In megaloblastic anemia: • Vit B12 • Folic acid Hematopoietic GFs • Erythropoietin (in chronic renal failure).

  4. Agents used to Tr anemia 1- Iron: Iron deficiency is ! most common cause of chronic anemia. Total Body Iron 4 g in ! adult male 2.5 g in ! adult female Source: meat & green vegetables.

  5. Iron forms ! nucleus of ! iron-porphyrin heme ring, which together with globin chains forms Hg. • Hg reversibly binds O2 (delivery). • Iron deficiency causes: small erythrocytes with insufficient Hg are formed: microcytic hypochromic anemia. PK: • All of ! iron used to support hematopoiesis is reclaimed from catalysis of ! Hg in aged / damaged erythrocytes.

  6. Dietary requirements are small & easily available in food. Iron absorption: Actively absorbed in duodenum & proximal jejunum. In ! ferric (+++) form & is complexed to other organic & inorganic molecules. ! acids in ! stomach & hydrolytic enzs in small intestine release ! iron from these complexes. It is then reduced to ! ferrous (++) form (more readily absorbed). Absorption is increased by: glucose, amino acids & ascorbic acid. & decreased by : phosphate bicarbonate bile acids, antacids & tetracycline. Heme iron in meat Hg & myoglobin can be absorbed intact. Iron in vegetables & grains, tightly bound to organic compounds; < available for absorption.

  7. Excess iron: stored in mucosal cell as ferritin, a water-soluble complex. Distribution: Iron is transported in ! plasma bound to transferrin, a β globulin binds 2 molecules of ferrous iron. ! iron is transported to ! marrow for use /storage. ! transferrin-iron complex enters maturing erythroid cells by a specific R mechanism.

  8. Storage: When free iron levels are high, apoferritin is produced to sequester iron & protect organs from toxic effect of excess free iron. Iron is stored in intestinal mucosal cells & as ferritin, in macrophages in liver, spleen, & bone.

  9. A- Uses of iron: • Treatment of iron deficiency anemia • Prevent anemia in increased iron requirement: - premature infants, - children during rapid growth periods, - pregnant & lactating women, - increased blood losses & iron (heavy menstruation), - patients with chronic kidney disease & treatment with GF erythropoietin (parenteral iron is preferred). - Malabsorption, inadequate iron absorption, GIT bleeding, gastrectomy & severe small bowel disease.

  10. B- Treatment Iron deficiency anemia is treated with po/ parenteral iron. po iron if GIT is normal. 1- Po iron: 200 – 400 mg for 3-6 months. Forms: FERROUS sulfate, gluconate, fumarate or succinate. All are effective & inexpensive.

  11. SE: N, epigastric discomfort, abdominal cramps, constipation/ diarrhea & black stools. Treatment: lower ! dose/ taking ! tablet immediately after/ with meal.

  12. 2- Parenteral iron; used in ! Following cases: (postgasrectomy, small bowel section, inflammatory bowel disease, noncompliance of po, malabsorption syndrome, marked blood loss & advanced chronic renal disease). • Iron dextran: stable complex of ferric hydroxide & low molecular weight dextran (IM/ IV infusion). Advantage of IV: eliminates local pain & tissue staining (SE: IM). + allow delivery of entire iron dose. • Also Iron sorbitol (IM)

  13. SE: headache, light-headness, fever, arthralgia, N, V, back pain, flushing, urticaria, Bronchospasm. Rare: anaphylaxis & death. Also dextran can cause hypersensitivity reactions. • Alternative preparations: Iron-sucrose complex & iron Na+ gluconate complex. ONLY (IV) less hypersensitivity than dextran.

  14. A- Acute iron tox: (multiple blood transfusions /acute child iron poisoning) Signs & symptoms: Necrotizing gastroenteritis, V, abdominal pain, bloody diarrhea, followed by shock, lethargy, & dyspnea. + severe metabolic acidosis, coma & death. Treatment: • Whole bowel irrigation/ gastric lavage: 1% NaHCO3. • Antidote: Deferoxamine (Desferroxamine), potent iron-chelating agent, bind absorbed iron & promote its excretion in urine & feces (intragastric, IM, SC, IV infusion).

  15. B- Chronic iron tox: Overload / hemochromatosis, result when excess iron is deposited in ! heart, liver, pancreas, & other organs. It can lead to organ failure & death. Causes: patients with inherited hemochromatosis (excessive iron abs;; tissue damage), & iron overload in patients who receive many RBCs transfusions over a long period of time as chronic hemolytic, microcytic anemia (thalassemias).

  16. Treatment tox: intermittent phlebotomy: Removing one unit of blood every week until all excess iron is removed. Or parenteral deferoxamine (less efficient, more complicated, expensive, & hazardous). • Recent oral iron chelator: deferasirox. Effective as deferoxamine at reducing liver iron conc & more convenient.

  17. 2- Cyanocobalamin = Vitamin B 12 (extrinsic F) CoFactor for several essential biochemical reactions. Its Deficiency;; anemia, GI symptoms, & neurological abnormalities. Chemistry: porphyrin-like ring with a central cobalt atom & nucleotide. Source: Meat (liver), eggs, & dairy products. For therapeutic use: Cyanocobalamin & hydroxycobolamin.

  18. PK: Stored mainly in liver Normal daily requirement: 2 -3 mcg. For its absorption, it makes a complex with intrinsic Factor, a glycoprotein secreted by ! parietal cells of ! gastric mucosa + R mediated transport system in ! lumen. Must be converted to active forms b4 absorption: Deoxy-adenosyl-cobalamin & methyl-cobalamin. Vit B12 deficiency results from malabsorption due to lack/loss/ malfunction of intrinsic F. This intrinsic F may be absent in gastrectomy & pernicious (megaloblastic) anemia. Nutritional deficiency (rare). Route of administration: mainly: parenteral,, IM Or po/ aerosol. Excretion: kidney.

  19. Pharmacodynamics: essential enzymatic rxs require Vit B12: Methylcobalamin: as intermediate in ! transfer of methyl gp from N-methylTHF to homocysterine, forming methionine & tetrahydrofolate (THFA). Required for purines & DNA synthesis. Depletion of THFA prevent ! synthesis of DNA. Treatment: Vit B12 + folic acid.

  20. Clinical pharm: Features of Vit B12 deficiency: • Impaired DNA synthesis; mainly RBCs • Megaloblastic anemia (macrocytic anemia + leukopenia &/ thrombocytopenia) • Hematologic abnormalities • GI symptoms • Neurological syndrome: paresthesia & weakness in peripheral nerves, spasticity, & ataxia.

  21. Causes of vit B12 deficiency: • Pernicious anemia (Defective secretion of intrinsic F by ! gastric mucosal cells). • Partial/ total gastrectomy • Malabsorption syndrome, inflammatory bowel syndrome or small bowel resection. • Damage of distal ileum that absorb vitB12-intrinsic F complex, • Surgical resection of ! ileum. TR: Vit B12.

  22. Tr: parenteral inj of vit B12. Available as: 1-Cyanocobalamin 2-Hydroxycobolamin is preferred (more highly protein bound: longer duration). Uses: 1- Pernicious (Addison) anemia 2- Neurologic abnormalities 3- Gastrectomy 4- Cyanide poisoning; Hydroxyocobalamin will bind circulating & cellular cyanide molecules to form cyanocobalamin which is excreted in ! urine .

  23. Initial therapy: 100-1000 mcg of vit B12 IM daily or every other day for 1-2 wks • Maintenance: 100-1000 mcg IM once a month for life. • Oral dose of 1000 mcg of vit B12 in pernicious anemia who refuse or cannot tolerate ! inj. • After parenteral, ! vit can also administered as a spray/ gel.

  24. Adverse effect of Vit B12 1- Allergic hypersensitivity reactions 2- Arrhythmia secondary to hypokalemia.

  25. 3- Folic acid (FA): Function: synthesis of amino acids, purines, pyrimidines, DNA & therefore cell division. Its deficiency is uncommon. deficiency of THFA causes anemia, congenital malformations in newborns & occlusive vascular D. Chemistry: FA is pteroglutamic acid, composed of pteridine, P-aminobenzoic acid + glutamic acid.

  26. FA can undergo reduction, catalyzed by DHFRase>> dihydroFA >>HFA (active form). • Vit B12 is required for activation of FA (demethylation). • PK: Source (as polyglutamate form): yeast, liver, kidney, & green vegetables. 5-20 mg of folates are stored in liver. Route: po Converted to mono-glutamyl form then absorbed in ! proximal jejunum . Excreted in urine & stool.

  27. Preparations: 1- Synthetic FA (tablets/ parenteral) 2- Folinic acid (5-formyl derivative of THFA, active form).

  28. FA Deficiency is caused by • Malabsorption & inadequate dietary intake of folate. • Alcohol dependence • Liver Disease. Clinical Pharm: • Folate deficiency; megaloblastic anemia. (1 mg po daily): reverse megaloblastic anemia, restore normal serum folate, & replenish body store of folate. • Prophylactically: Pregnant women & patients with hemolytic anemia have increase folate requirements & may become FA-deficient, esp if their diets are marginal. • Maternal FA deficiency: fetal neural tube defect as spina bifida.

  29. Patients who require renal dialysis. • Drugs: Methotrexate, trimethoprim & pyrimethamine inhibit DHFRase: deficiency of folate CoFs;; megaloblastic anemia. • Long term use of phenytoin • H risk patients (FA supplementation): pregnancy, premature infants, hemolytic anemia, liver D, & renal dialysis.

  30. 4- Hematopoietic Growth Factors: Glycoprotein hormones regulate ! proliferation & differentiation of hematopoietic progenitor cells in Bone marrow. Produced by recombinant DNA technology.

  31. Erythropietin : Produced in ! Kidney 1- Epotein: PK: • IV/ SC • T1/2: 4-13 hr • Not cleared by dialysis. • Given 2-3 times weekly. 2- Darbepoetin (α): glycosylate form, longer t1/2.

  32. Pharmacodynamics: 1- Stimulate erythroid proliferation & differentiation by interacting with specific erythropoietin Rs on RBC progenitors. 2- Induces release of reticulocytes from bone marrow (BM) 3- Tissue hypoxia stimulate erythropoietin synthesis.

  33. Clinical Pharm/ Uses: 1- Anemia + chronic renal failure Erythropoietin 50-150 IU/kg, IV/SC: improve ! hematocrit (in 10 days) & Hg level (in 2-6 wk) & eliminate ! need for transfusion + Iron & FA. 2- Anemia in HIV patients & zidovudine (anti HIV). 3- Anemia in cancer patients. 4- Anemia due to BM disorders. As in patients with aplastic anemia & other BM failure states, & multiple myeloma. 5- Anemia associated with chronic inflammation (RA) 7- Anemia of prematurity 8- To accelerate erythropoiesis after phlebotomies. 9- Misused by athletes to increase O2 delivery & performance.

  34. Adverse effects &Toxicity: 1- Rapid increase of hematocrit & Hg: HTN & thrombosis. 2- Seizure, headache 3- Transient influenza-like syndrome 4- Mild allergic reactions.

More Related